The Day Wall Street Opened the Door to an Industry That Barely Existed

Listen to the audio version of this article (generated by AI).

In January 1976, a 28-year-old venture capitalist named Robert Swanson called a biochemist at the University of California, San Francisco.

The scientist, Herbert Boyer, had helped develop a method for cutting and recombining DNA. Swanson believed the discovery could become the foundation of an entirely new kind of drug company.

Boyer agreed to give him 10 minutes.

They met at a San Francisco bar. Ten minutes became several hours and a few beers. By the end of the conversation, the two men had agreed to start a company.

They called it Genentech – short for genetic engineering technology.

Four years later, Genentech went public.

Biotechnology was not yet an established industry. Genentech had demonstrated that bacteria could be engineered to produce human proteins, including insulin, but no genetically engineered medicine had been approved for sale in the United States.

Public investors bought the possibility anyway.

Genentech offered one million shares at $35 apiece on October 14, 1980. Within the first hour, the price climbed as high as $88. It closed the day at $71.25.

The investors who bought that day were not there when Swanson and Boyer started the company over beers. But they did arrive before the first genetically engineered human medicine won approval in 1982. Before Genentech brought its own drug to market. Before biotechnology became a multi trillion–dollar global industry.

In other words, the opening bell opened a door while almost the entire opportunity remained on the other side.

For much of the modern stock market’s history, that was normal.

It is not normal anymore.

IPOs No Longer Mark the Beginning

Genentech reached Wall Street four years after it was founded. Microsoft Corp. (MSFT) took 11 years. Nvidia Corp. (NVDA) took six.

Those companies were already promising when they reached Wall Street. But they were still young enough that ordinary investors could participate in decades of expansion.

The public market helped finance the journey.

Today, the journey often happens somewhere else.

The most ambitious technology companies can spend 10, 15, or even 20 years growing before they seriously consider an IPO. During that time, they can develop products, build infrastructure, hire thousands of employees, sign enormous contracts, and reach valuations once reserved for the largest publicly traded corporations.

By the time the ticker appears, the company may no longer resemble the speculative young business Genentech investors encountered in 1980.

It may already be a global institution.

That does not mean investors cannot make money after an IPO. Many companies continue creating tremendous value long after their public debuts.

But the starting point matters.

Buying a four–year–old company before its first approved product is a fundamentally different proposition from buying a mature business whose value has already climbed into the hundreds of billions.

The opening bell used to invite investors into the company’s defining growth chapter.

Increasingly, it announces that the chapter has already been written.

Why AI Companies Can Stay Private Longer

This shift has been building for years. Artificial intelligence is accelerating it.

Young companies once needed Wall Street to raise the money required for large–scale expansion. Going public gave them capital, credibility, and shares they could use to attract employees or acquire competitors.

Today’s most promising AI companies can find extraordinary amounts of capital without entering the public market.

That changes the calculation.

An IPO brings money, but it also brings quarterly earnings expectations, extensive disclosures, regulatory obligations, and constant scrutiny. If a company can fund its growth without accepting those burdens, its leaders may decide there is little reason to rush.

AI also creates another possible ending.

The largest technology companies are racing to secure models, data, chips, energy, robotics, cybersecurity, and specialized talent. When a young company solves a problem that one of those giants considers urgent, it may receive a partnership, investment, or acquisition offer long before an IPO becomes necessary.

In that case, the opening bell does not merely arrive late.

It never arrives.

That is how an important part of the AI economy can remain almost invisible to ordinary investors. They see the breakthrough after a technology giant announces it. They see the new product after it has been folded into a larger platform. They see the effect on a public company’s earnings months or years later.

But the original value was created before any familiar ticker told them where to look.